Measuring the Gains from Medical Research: An Economic ApproachKevin M. Murphy, Robert H. Topel University of Chicago Press, 2010 M04 15 - 240 páginas In 1998, health expenditures in the United States accounted for 12.9% of national income-the highest share of income devoted to health in the developed world. The United States also spends more on medical research than any other country-in 2000, the federal government dedicated $18.4 billion to it, compared with only $3.7 billion for the entire European Union. In this book, leading health economists ask whether we are getting our money's worth. From an economic perspective, they find, the answer is a resounding "yes": in fact, considering the extraordinary value of improvements to health, we may even be spending too little on medical research. The evidence these papers present and the conclusions they reach are both surprising and convincing: that growth in longevity since 1950 has been as valuable as growth in all other forms of consumption combined; that medical advances producing 10% reductions in mortality from cancer and heart disease alone would add roughly $10 trillion-a year's GDP-to the national wealth; or that the average new drug approved by the FDA yields benefits worth many times its cost of development. The papers in this book are packed with these and many other surprising revelations, their sophisticated analysis persuasively demonstrating the massive economic benefits we can gain from investments in medical research. For anyone concerned about the cost and the value of such research-from policy makers to health care professionals and economists-this will be a landmark book. |
Contenido
1 | |
9 | |
2 The Economic Value of Medical Research | 41 |
3 Pharmaceutical Innovation Mortality Reduction and Economic Growth | 74 |
Treatment and Behavioral Effects | 110 |
TheCauses of Technological Change in Heart Attack Treatment | 163 |
6 Can Medical CostEffectiveness Analysis Identify the Value of Research? | 206 |
Contributors | 249 |
251 | |
255 | |
Otras ediciones - Ver todas
Measuring the Gains from Medical Research: An Economic Approach Kevin M. Murphy,Robert H. Topel Sin vista previa disponible - 2003 |
Términos y frases comunes
ACE inhibitors Acute Myocardial Infarction acute treatment angioplasty approach aspirin average behavioral benefits beta-blockers biomedical research calcium channel blockers calculations cardiovascular disease cause cigarette clinical practice clinical trials consumption coronary heart disease cost-effectiveness analysis Cutler death rates decision drugs approved drugs prescribed economic effects equation estimates evidence example expected utility expected value FIGURE formal research funding future costs gains growth health expenditures health income health status heart attack high blood pressure hypertension impact important improvements in health increase individual life-years lost longevity marginal Mark McClellan McClellan measure medical cost-effectiveness analysis medical interventions medical knowledge medical research medical treatments Meltzer mortality reduction National new-drug share outcomes Pap smear per-capita percent period pharmaceutical innovation population primary angioplasty prostate cancer QALYs quality-adjusted ratio reduced mortality risk factors significant smoking sources spending streptokinase studies suggest surveys therapy thrombolytic tion trends trillion vaccine
Referencias a este libro
Hidden Costs, Value Lost: Uninsurance in America Institute of Medicine,Board on Health Care Services,Committee on the Consequences of Uninsurance Sin vista previa disponible - 2003 |